Oseltamivir - Revision history

Sabedi: /* Special Populations */

2020-02-25T22:52:56Z

Special Populations

← Older revision		Revision as of 22:52, 25 February 2020
Line 40:		Line 40:
	===Hepatic Dosing===		===Hepatic Dosing===
	*efficacy in hepatic impairment has not been established		*efficacy in hepatic impairment has not been established

			===Chemoprophylaxis===
			*In general, Centers for Disease Control does not recommend seasonal or pre-exposure antiviral chemoprophylaxis, but can be considered in certain situations:
			**Patients at high risk of influenza complications during the first two weeks following vaccination after exposure to a person with influenza.
			**Patients who cannot receive influenza vaccine due to a contraindication after exposure to a person with influenza.
			**Prevention for people with severe immune deficiencies or others who might not respond to influenza vaccination, such as people receiving immunosuppressive medications, after exposure to a person with influenza.
			*To be effective as chemoprophylaxis, an antiviral medication must be taken each day for the duration of potential exposure to a person with influenza and continued for 7 days after the last known exposure. For people taking antiviral chemoprophylaxis after inactivated influenza vaccination, the recommended duration is until immunity after vaccination develops (antibody development after vaccination takes about two weeks in adults and can take longer in children depending on age and vaccination history).
			*Antiviral chemoprophylaxis generally is not recommended if more than 48 hours have elapsed since the first exposure to a person with influenza.

	==Contraindications==		==Contraindications==

Sabedi: /* Renal Dosing */

2020-02-25T22:46:17Z

Renal Dosing

← Older revision		Revision as of 22:46, 25 February 2020
Line 33:		Line 33:
	**Nursing home or chronic care facility residents.		**Nursing home or chronic care facility residents.
	===Renal Dosing===		===Renal Dosing===
	*CrCl >30 to 60 mL/minute: 30mg BID for 5 days		*CrCl >31 to 60 mL/minute: 30mg BID for 5 days
	*CrCl >10 to 30 mL/minute: 30mg qday for 5 days		*CrCl >11 to 30 mL/minute: 30mg qday for 5 days
	*ESRD ~~not undergoing dialysis~~: ~~Use is not recommended~~ (~~efficacy in ESRD has~~ not ~~been established.~~)		*ESRD on HD CrCl≤10 mL/minute: 30mg after every hemodialysis cycle (treatment duration not to exceed 5 days)
			*ESRD patients on Continuous Ambulatory Peritoneal Dialysis CrCl≤10 mL/minute: Single 30mg dose administered immediately after dialysis exchange

	===Hepatic Dosing===		===Hepatic Dosing===
	*efficacy in hepatic impairment has not been established		*efficacy in hepatic impairment has not been established

ClaireLewis at 00:48, 23 September 2019

2019-09-23T00:48:08Z

← Older revision		Revision as of 00:48, 23 September 2019
Line 50:		Line 50:

	===Common===		===Common===
	*abdominal pain, nausea/vomiting		*abdominal pain, nausea/vomiting, diarrhea
			*Insomnia


	==Pharmacology==		==Pharmacology==
	*Half-life:		*Half-life: 1-3h
	*Metabolism:		*Metabolism:
	*Excretion:		*Excretion:
Line 72:		Line 74:
	<references/>		<references/>
	[[Category:Pharmacology]]		[[Category:Pharmacology]]
			[[Category:ID]]

Mholtz: Text replacement - "-->" to "→"

2017-02-08T17:04:24Z

Text replacement - "-->" to "→"

← Older revision		Revision as of 17:04, 8 February 2017
Line 58:		Line 58:

	==Mechanism of Action==		==Mechanism of Action==
	*inhibits viral ~~neuroaminidase-->~~ interferes with viral particle release		*inhibits viral neuroaminidase→ interferes with viral particle release

	==Comments==		==Comments==

Rossdonaldson1: /* Administration */

2017-02-01T12:17:11Z

Administration

← Older revision		Revision as of 12:17, 1 February 2017
Line 1:		Line 1:
	==Administration==		==Administration==
	*Type: Antiviral		*Type: [[Antiviral]]
	*Routes of Administration: Oral		*Routes of Administration: Oral
	*Common Trade Names: Tamiflu		*Common Trade Names: Tamiflu

Neil.m.young: Text replacement - "* " to "*"

2016-08-03T18:05:49Z

Text replacement - "* " to "*"

← Older revision		Revision as of 18:05, 3 August 2016
Line 44:		Line 44:
	==Adverse Reactions==		==Adverse Reactions==
	===Serious===		===Serious===
	* dysrhythmia		*dysrhythmia
	*erythema multiforme/TEN/SJS		*erythema multiforme/TEN/SJS
	*GI bleed, hepatitis		*GI bleed, hepatitis

Rossdonaldson1: Text replacement - "HTN" to "hypertension"

2016-07-31T12:41:23Z

Text replacement - "HTN" to "hypertension"

← Older revision		Revision as of 12:41, 31 July 2016
Line 23:		Line 23:
	**Adults > 65 yo		**Adults > 65 yo
	**Chronic Pulmonary Disease including Asthma		**Chronic Pulmonary Disease including Asthma
	**Cardiovascular disease (excluding ~~HTN~~ only)		**Cardiovascular disease (excluding hypertension only)
	**Renal, hepatic, hematological, and metabolic disorders (including sickle cell, diabetes)		**Renal, hepatic, hematological, and metabolic disorders (including sickle cell, diabetes)
	**Neurological and Neurodevelopmental disorders (brain disorders, spinal cord, peripheral nerve disorders, cerebreal palsy, epilepsy, stroke, MR, developmental delay, muscular dystrophy)		**Neurological and Neurodevelopmental disorders (brain disorders, spinal cord, peripheral nerve disorders, cerebreal palsy, epilepsy, stroke, MR, developmental delay, muscular dystrophy)

Neil.m.young: Text replacement - "0 mg" to "0mg"

2016-07-20T12:54:43Z

Text replacement - "0 mg" to "0mg"

← Older revision		Revision as of 12:54, 20 July 2016
Line 33:		Line 33:
	**Nursing home or chronic care facility residents.		**Nursing home or chronic care facility residents.
	===Renal Dosing===		===Renal Dosing===
	*CrCl >30 to 60 mL/minute: ~~30 mg~~ BID for 5 days		*CrCl >30 to 60 mL/minute: 30mg BID for 5 days
	*CrCl >10 to 30 mL/minute: ~~30 mg~~ qday for 5 days		*CrCl >10 to 30 mL/minute: 30mg qday for 5 days
	*ESRD not undergoing dialysis: Use is not recommended (efficacy in ESRD has not been established.)		*ESRD not undergoing dialysis: Use is not recommended (efficacy in ESRD has not been established.)
	===Hepatic Dosing===		===Hepatic Dosing===

Rossdonaldson1: Text replacement - "n/v" to "nausea and vomiting"

2016-07-14T18:11:14Z

Text replacement - "n/v" to "nausea and vomiting"

← Older revision		Revision as of 18:11, 14 July 2016
Line 62:		Line 62:
	==Comments==		==Comments==
	*Influenza		*Influenza
	**Shortens duration of illness by 16.8 hrs while NNTH (number needed to harm) was 28 in regards to causing ~~n/v~~, HA, and renal and psych syndromes<ref>Jefferson T, et al. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014; 348:g2545.</ref>		**Shortens duration of illness by 16.8 hrs while NNTH (number needed to harm) was 28 in regards to causing nausea and vomiting, HA, and renal and psych syndromes<ref>Jefferson T, et al. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014; 348:g2545.</ref>
	**Greatest benefit if within 48hrs of symptom onset<ref>CDC Guidelines. 2015-2016. http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm</ref>		**Greatest benefit if within 48hrs of symptom onset<ref>CDC Guidelines. 2015-2016. http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm</ref>
	***However, may be beneficial up to 4-5 days, including in pregnant patients		***However, may be beneficial up to 4-5 days, including in pregnant patients

ClaireLewis: /* Special Populations */

2016-07-12T21:12:16Z

Special Populations

← Older revision		Revision as of 21:12, 12 July 2016
Line 17:		Line 17:

	==Special Populations==		==Special Populations==
	*[[Drug Ratings in Pregnancy\|Pregnancy Rating]]:C		*[[Drug Ratings in Pregnancy\|Pregnancy Rating]]: Category C
	*[[Lactation risk categories\|Lactation risk]]: Low concentrations of oseltamivir seen in breast milk; levels are unlikely to lead to toxicity in a breast-fed infant. The manufacturer recommends that caution be used if administered to a nursing woman.		*[[Lactation risk categories\|Lactation risk]]: Low concentrations of oseltamivir seen in breast milk; levels are unlikely to lead to toxicity in a breast-fed infant. The manufacturer recommends that caution be used if administered to a nursing woman.
	*High Risk for Complications and Recommended for Treatment per CDC:		*High Risk for Complications and Recommended for Treatment per CDC: